Director's Share Dealings
February 21, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")
announces it was notified on February 20, 2014 that on that day, Matthew
Emmens, the Company's Chairman, sold 36,100 Ordinary Shares in the Company
("Shares") at an average sale price of £33.14853. The Shares were sold on the
London Stock Exchange.
Following the above transaction, Mr Emmens holds 56,774 Shares and 5,872
American Depositary Shares in the Company ("ADSs"). Each ADS represents three
This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules.
Deputy Company Secretary
For further information please contact:
Laurie Stelzer firstname.lastname@example.org +1 858 754 5480
Eric Rojas email@example.com +1 781 482 0999
Sarah Elton-Farr firstname.lastname@example.org +44 1256 894157
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and
Internal Medicine and we are developing treatments for symptomatic conditions
treated by specialist physicians in other targeted therapeutic areas.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
-0- Feb/21/2014 12:00 GMT
Press spacebar to pause and continue. Press esc to stop.